Santarus' 1Q13 earnings beat Street

Santarus Inc. (NASDAQ:SNTS) jumped $2.13 (11%) to $21 in early after-hours trading after announcing 1Q13 earnings late Monday that beat the Street. Total revenues for the quarter were $79.4 million, including $41.5 million in net sales of diabetes drug Glumetza extended-release metformin tablets and up 73% from $45.9 million in 1Q13. The Street was expecting $74.7 million. First quarter diluted GAAP EPS was $0.25, up from $0.01 in 1Q12 and beating by $0.11 the Street's estimate of $0.14. Santarus raised its 2013 revenue guidance to about $330-$340 million from $320-$325 million. The Street was expecting 2013 revenues of $339.3 million. ...